JENA/Germany, BENSHEIM/Germany, ASUNCIÒN/Paraguay, 2018-02-28.
Training and continuing education of ophthalmologists are a key factor in the fight against preventable blindness – particularly in remote regions. ZEISS and the Christoffel-Blindenmission (CBM), along with local partner Fundación Visión, have now set up a new training center dedicated to cataract surgery in Asunción (Paraguay). This center trains ophthalmologists in the state-of-the-art surgical technique of phacoemulsification.
“With this center we are jointly establishing ophthalmic care in the region that offers patients the greatest possible level of safety,” says CBM CEO, Dr. Rainer Brockhaus. He adds: “It means that poorer people can also benefit from a better quality of treatment.” Dr. Ludwin Monz, member of the ZEISS executive board responsible for the Medical Technology segment, expands: “The new Phaco Training Center is the result of the many years of targeted collaboration between CBM and ZEISS and our local partner Fundación Visión.”
Physicians and nursing staff from the partner clinic in Asunción will be trained in the extended training center, to which ZEISS has donated two surgical microscopes and two phaco systems, among other things. In future, the new training program will be offered to physicians from all over South America.
CBM and ZEISS have been jointly supporting the eye clinic operated by Fundación Visión with equipment and training since 2013; in 2017 alone, a total of 19 physicians operated on almost 5,000 cataract patients from throughout the region. The aim of the new training center is for even more people to benefit from the best treatment. Fundación Visión will cover the costs for poor people who cannot afford the treatment.
Training and educating physicians brings huge benefits for the health and quality of life of the population. One person who has benefited is ten-year-old Ramon from José Fassardi, a village situated around 200 kilometers southeast of Asunción: Ramon had cataracts in both eyes, a clouding of the lens of the eye, and was virtually blind. He had a hard time following his lessons in school. He was operated on at the eye clinic of our local partner in Asunción using the state-of-the-art and safe phaco-technology, and now he can see again. Ramon is now a happy and eager participant in his lessons and enjoys playing football with his friends in his free time.
Phacoemulsification – cutting-edge technology in ophthalmology
Phacoemulsification is the step during eye surgery, during which the natural lens of the eye, which has become clouded due to cataracts, is shattered using an ultrasound device and then sucked out. An artificial intraocular lens is then placed inside the empty lens capsule. This procedure is state of the art and has been established in Germany and the USA, for example, for several decades. The procedure has been much slower to reach countries such as Paraguay, however, and in many places it is not available in all areas. “This collaboration means that we are jointly helping to establish state-of-the-art ophthalmic techniques in countries like Paraguay,” summarizes Dr. Ludwin Monz.
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,000 employees worldwide, the Group generated revenue of €1,189.9m in fiscal year 2016/17 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at:
CBM is a Christian international development organization, committed to improving the quality of life of people with disabilities in the poorest communities of the world irrespective of race, gender or religious belief. Based on its core values and over 100 years of professional expertise, CBM addresses poverty both as a cause and as a consequence of disability, and works in partnership with local and national civil society organizations to create an inclusive society for all.
For more information visit www.cbm.org